Investigational drug therapies for the treatment of gastroparesis

References

• Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterol. 2009;136:1225–1233.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Camilleri M, Kuo B, et al. Development and content validity of a gastroparesis cardinal symptom index daily diary. Aliment Pharmacol Ther. 2009;30:670–680.
   PubMed Web of Science ®Google Scholar
• Lu PL, Moore-Clingenpeel M, Yacob D, et al. The rising cost of hospital care for children with gastroparesis: 2004–2013. Neurogastroenterol Motil. 2016;28:1698–1704. DOI:10.1111/nmo.12869
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Yates KP, Nguyen L, et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterol. 2015;149:1762–1774.
   PubMed Web of Science ®Google Scholar
• Bharucha AE. Epidemiology and natural history of gastroparesis. Gastroenterol Clin North Am. 2015;44:9–19.
   PubMed Web of Science ®Google Scholar
• Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000;95:1456–1462.
   PubMed Web of Science ®Google Scholar
• Rey E, Choung RS, Schleck CD, et al. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J Neurogastroenterol Motil. 2012;18:34–42.
   PubMed Web of Science ®Google Scholar
• Choung RS, Locke GR 3rd, Schleck CD, et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012;107:82–88.
   PubMed Web of Science ®Google Scholar
• Olausson EA, Storsrud S, Grundin H, et al. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol. 2014;109:375–385.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108:18–37.
   PubMed Web of Science ®Google Scholar
• Stevens JE, Jones KL, Rayner CK, et al. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. Expert Opin Pharmacother. 2013;14:1171–1186.
   PubMed Web of Science ®Google Scholar
• Sanger GJ. Translating 5-HT4 receptor pharmacology. Neurogastroenterol Motil. 2009;21:1235–1238.
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci: Basic Clinical. 2006;129:3–16.
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Pehlivanov N, Segumar A, et al. Drug insight: from disturbed motility to disordered movement – a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Praqct Gastroenterol Hepatol. 2006;3:138–148.
   PubMedGoogle Scholar
• Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94:1230–1234.
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Wang Y-T, Hobson A, et al. Motilin: toward a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol. 2013;170:1323–1332.
   PubMed Web of Science ®Google Scholar
• Broad J, Mukherjee S, Samadi M, et al. Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol. 2012;167:763–774.
   PubMed Web of Science ®Google Scholar
• Broad J, Sanger GJ. The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol. 2013;168:1859–1867.
   PubMed Web of Science ®Google Scholar
• Potter TG, Snider KR. Azithromycin for the treatment of gastroparesis. Ann Pharmacother. 2013;47:411–415.
   PubMed Web of Science ®Google Scholar
• Javid FA, Bulmer DC, Broad J, et al. Anti-emetic and emetic effects of erythromycin in Suncus murinus: potential role of vagal activation, increased gastric motility and motilin receptors. Eur J Pharmacol. 2013;699:48–54.
   PubMed Web of Science ®Google Scholar
• Petrakis EE, Kogerakis N, Vrachassotakis N, et al. Hyperglycaemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in healthy subjects. Abdom Imaging. 2002;27:309–314.
   PubMedGoogle Scholar
• McCallum RW, Fink SM, Lerner E, et al. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterol. 1983;84:1573–1577.
   PubMed Web of Science ®Google Scholar
• Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175–182.
   PubMed Web of Science ®Google Scholar
• Broad J, Góralczyk A, Mannur K, et al. Drugs acting at 5-HT4, D2, motilin and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach. Neurogastroenterol Motil. 2014;26:851–861.
   PubMed Web of Science ®Google Scholar
• Markey O, Shafat A. Does domperidone, a D2-antagonist alter gastric emptying rates and appetite sensations in healthy adults with high-fat meal? A block-randomised, single-blind placebo-controlled study. Ir J Med Sci. 2012;181:215–219.
   PubMed Web of Science ®Google Scholar
• Chen H-L, Hsiao F-Y. Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case–crossover study. Pharmacoepidemiol Drug Safety. 2015. DOI:10.1002/pds
   Google Scholar
• Andrews PLR, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol. 2014;722:108–121.
   PubMed Web of Science ®Google Scholar
• Amin K, Bastani B. Intraperitoneal ondansetron hydrochloride for intractable nausea and vomiting due to diabetic gastroparesis in a patient on peritoneal dialysis. Perit Dial Int. 2002;22:539–540.
   PubMed Web of Science ®Google Scholar
• Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmaol Exp Ther. 1997;283:1305–1322.
   PubMed Web of Science ®Google Scholar
• Prakash C, Lustman PJ, Freedland KE, et al. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci. 1998;43:1951–1956.
   PubMed Web of Science ®Google Scholar
• Sawhney MS, Prakash C, Lustman PJ, et al. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci. 2007;52:418–424.
   PubMed Web of Science ®Google Scholar
• Parkman HP, van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis. The NORIG randomized clinical trial. Jama. 2013;310:2640–2649.
   PubMed Web of Science ®Google Scholar
• Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7:249–264.
   PubMedGoogle Scholar
• Kim S-W, Shin I-S, Kim J-M, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics. 2006;47:440–442.
   PubMed Web of Science ®Google Scholar
• Kundu S, Rogal S, Alam A, et al. Rapid improvement in post-infectious gastroparesis symptoms with mirtazapine. Wld J Gastroenterol. 2014;20:6671–6674.
   PubMed Web of Science ®Google Scholar
• Jiang S-M, Jia L, Liu J, et al. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. Wld J Gastroenterol. 2016;22:5260–5266.
   PubMed Web of Science ®Google Scholar
• Yin J, Song J, Lei Y, et al. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol. 2014;306:G796–801.
   PubMed Web of Science ®Google Scholar
• Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014;22:1143–1151.
   PubMed Web of Science ®Google Scholar
• Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterol. 1986;90:1919–1925.
   PubMed Web of Science ®Google Scholar
• Bromer MQ, Friedenberg F, Miller LS, et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005;61:833–839.
   PubMed Web of Science ®Google Scholar
• Bai Y, Xu MJ, Yang X, et al. A systematic review of intrapyloric botulinum toxin injection for gastroparesis. Digestion. 2010;81:27–34.
   PubMed Web of Science ®Google Scholar
• Stern RM, Koch KL, Andrews PLR. Nausea: mechanisms and Management. NY, USA: Oxford University Press; 2011. .
   Google Scholar
• Jordan K, Warr DG, Hinke A, et al. Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis. Support Care Cancer. 2016;24:1941–1954.
   PubMed Web of Science ®Google Scholar
• Angeli TR, Cheng LK, Du P, et al. Loss of interstitial cells of Cajal and patterns of gastric dysrhythmia in patients with chronic unexplained nausea and vomiting. Gastroenterol. 2015;149:56–66.
   PubMed Web of Science ®Google Scholar
• Farmer AD, Ban VF, Coen SJ, et al. Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans. J Physiol. 2015;593.5:1183–1196.
   Web of Science ®Google Scholar
• Sanger GJ, Furness JB. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders. Nature Rev Gastroenterol Hepatol. 2016;13:38–48.
   PubMed Web of Science ®Google Scholar
• Janssen P, Harris MS, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol. 2013;108:1382–1391.
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol. 2011;9:567–576.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Choi S, Im W. 5-HT4 receptor agonists in the treatment of gastrointestinal motility disorders: current status and perspective. Int J Gastroenterol Disord Ther. 2014;1:108. DOI:10.15344/2393-8498/2014/108
   Google Scholar
• Tack J, Rotondo A, Meulemans A, et al. Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis. Neurogastroenterol Motil. 2016;28:487–497.
   PubMed Web of Science ®Google Scholar
• Broad J, Takahashi N, Tajimi M, et al. RQ-00201894: A motilin receptor agonist causing long-lasting facilitation of human gastric cholinergically-mediated contractions. J Pharmacol Sci. 2016;130:60–65.
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Westaway SM, Barnes AA, et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil. 2009;21:657–666.
   PubMed Web of Science ®Google Scholar
• Westaway SM, Brown SL, Fell SCF, et al. Discovery of N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040): the first small molecule motilin receptor agonist clinical candidate. J Med Chem. 2009;52:1180–1189.
   PubMed Web of Science ®Google Scholar
• Barshop K, Kuo B. The investigational drug camicinal for the treatment of gastroparesis. Exp Opin Investig Drugs. 2014;24:1–8.
   PubMed Web of Science ®Google Scholar
• Dukes GE, Barton M, Dewit O, et al. Safety/tolerability, pharmacokinetics (PK), and effect on gastric emptying (GE) with 14-days repeat oral dosing of the motilin receptor agonist, GSK962040, in healthy male and female volunteers. Neurogastroenterol Motil. 2010;22(S1):14–15.
   Google Scholar
• Hobson R, Farmer AD, Dewit OE, et al. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial. Neurogastroenterol Motil. 2015;27:1629–1637.
   PubMed Web of Science ®Google Scholar
• Broad J, Hughes F, Chin-Aleong J, et al. Regionally-dependent neuromuscular functions of motilin and 5-HT4 receptors in human isolated esophageal body and gastric fundus. Neurogastroenterol Motil. 2014;26:1311–1322.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Deane AM, O’Connor SL, et al. The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. Crit Care. 2016;20:232.
   PubMed Web of Science ®Google Scholar
• Hellström PM, Tack J, Johnson LV, et al. The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. Br J Pharmacol. 2016;173:1768–1777.
   PubMed Web of Science ®Google Scholar
• Barton ME, Otiker T, Vasist Johnson LS, et al. A randomized, double-blind, placebo-controlled phase II study (MOT114479) to evaluate the safety and efficacy and dose response of 28 days of orally administered camicinal, a motilin receptor agonist, in diabetics with gastroparesis [abstract]. Gastroenterol. 2014;146(Suppl 1):S20.
   Google Scholar
• Koch KL. Gastric dysrhythmias: a potential objective measure of nausea. Exp Brain Res. 2014;232:2553–2561. .
   PubMed Web of Science ®Google Scholar
• Bradshaw LA, Cheng LK, Chung E, et al. Diabetic gastroparesis alters the biomagnetic signature of the gastric slow wave. Neurogastroenterol Motil. 2016;28:837–848.
   PubMed Web of Science ®Google Scholar
• O’Grady G, Angeli TR, Du P, et al. Abnormal initiation and conduction of slow-wave activity in gastroparesis, defined by high-resolution electrical mapping. Gastroenterol. 2012;143:589–598.
   PubMed Web of Science ®Google Scholar
• O’Grady G, Wang T, Du P, et al. Recent progress in gastric arrhythmia: pathophysiology, clinical significance and future horizons. Clin Exp Pharmacol Physiol. 2014;41:854–862.
   PubMed Web of Science ®Google Scholar
• Lees-Green R, Du P, O’Grady G, et al. Biophysically based modelling of the interstitial cells of Cajal: current status and future perspectives. Frontiers in Physiology. 2011; 2, article29: 1–19.
   Google Scholar
• Forster J, Damjanov I, Lin Z, et al. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg. 2005;9:102–108.
   PubMed Web of Science ®Google Scholar
• Grover M, Farrugia G, Lurken MS, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterol. 2011;140:1575–1585.
   PubMed Web of Science ®Google Scholar
• Grover M, Bernard CE, Pasricha PJ, et al. Clinical-histological associations in gastroparesis: results from the gastroparesis clinical research consortium. Neurogastroenterol Motil. 2012;24:531–539.
   PubMed Web of Science ®Google Scholar
• Moraveji S, Bashashati M, Elhanafi S, et al. Depleted interstitial cells of Cajal and fibrosis in the pylorus: novel features of gastroparesis. Neurogastroenterol Motil. 2016;28:1048–1054.
   PubMed Web of Science ®Google Scholar
• Mazzone A, Bernard CE, Strege PR, et al. Altered expression of Ano1 variants in human diabetic gastroparesis. J Biol Chem. 2011;286:13393–13403.
   PubMed Web of Science ®Google Scholar
• Bersherdas K, Leahy A, Mason I, et al. The effect of cisapride on dyspepsia symptoms and the electrogastrogram in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 1998;12:755–759.
   PubMed Web of Science ®Google Scholar
• Rothstein R, Alavi A, Reynolds J. Electrogastrography in patients with gastroparesis and effect of long term cisapride. Dig Dis Sci. 1993;38:1518–1524.
   PubMed Web of Science ®Google Scholar
• Russell JL. Relatively low doses of cisapride in the treatment of nausea in patients treated with venlofaxine for treatment refractory depression. J Clin Psychopharmacol. 1996;16:35–37.
   PubMed Web of Science ®Google Scholar
• Sanger GJ. 5-Hydroxytryptamine and the gastrointestinal tract: where next? Trends Pharmacolol Sci. 2008;29:465–471.
   PubMed Web of Science ®Google Scholar
• Akbarali HI, Thatte H, He XD, et al. Role of HERG-like K(+) currents in opossum esophageal circular smooth muscle. Am J Physiol. 1999;277:C1284–90.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Golden CM, Ye J, et al. ERG K+ currents regulate pacemaker activity in ICC. Am J Physiol. 2003;285:G1249–58.
   PubMed Web of Science ®Google Scholar
• Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores natural nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest. 2000;106:373–384.
   PubMed Web of Science ®Google Scholar
• Bianco A, Pitocco D, Valenza V, et al. Effect of sildenafil on diabetic gastropathy. Diabetes Care. 2002;25:1888–1889.
   PubMed Web of Science ®Google Scholar
• Dishy V, Cohen Pour M, Feldman, L., et al. The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis. Clin Pharmacol Ther. 2004;76:281–286.
   PubMed Web of Science ®Google Scholar
• Cho SH, Park H, Kim JH, et al. Effect of sildenafil on gastric emptying in healthy adults. J Gastroenterol Hepatol. 2006;21:222–226.
   PubMed Web of Science ®Google Scholar
• Wu R, Dong W, Ji Y, et al. Orexigenic hormone ghrelin attenuates local and remote organ injury after intestinal ischemia-reperfusion. Plos One. 2008;3:e2026.
   PubMed Web of Science ®Google Scholar
• Horvath VJ, Vittal H, Lorincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterol. 2006;130:759–770.
   PubMed Web of Science ®Google Scholar
• Neshatian L, Gibbons SJ, Farrugia G. Macrophages in diabetic gastroparesis - the missing link? Neurogastroenterol Motil. 2015;27:7–18. .
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Daley SL, Low PA, et al. Effects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis. Neurogastroenterol Motil. 2016;28:1731–1740. DOI:10.1111/nmo.12874
   PubMed Web of Science ®Google Scholar
• Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012;10:1239–1245.
   PubMed Web of Science ®Google Scholar
• Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2832–2836.
   PubMed Web of Science ®Google Scholar
• Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients. Cancer. 2012;118:4785–4794.
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Rupprecht LE, Fortin SM, et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacol. 2012;62:1916–1927.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A. Emerging treatments in neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil. 2015;27:324–332.
   PubMed Web of Science ®Google Scholar
• Sha L, Farrugia G, van der Ploeg LHT, et al. Effect of RM-131 on circular smooth muscle cells in human and mouse colon and on colonic intraluminal pressure in conscious mice. Gastroenterol. 2014;146(Suppl. 1):S363.
   Google Scholar
• Shin A, Camilleri M, Busciglio I, et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol. 2013;11:1453–1459.
   PubMed Web of Science ®Google Scholar
• Nelson AD, Camilleri M, Acosta A, et al. Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. Neurogastroenterol Motil. 2016;28:1705–1713. DOI:10.1111/nmo.12870
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M, McCallum R, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterol. 2014;146(Suppl. 1):S158–9.
   Google Scholar
• Lembo A, Camilleri M, McCallum R, et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterol. 2016;151:87–96.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Gastroparesis: clinical evaluation of drugs for treatment - guidance for industry. (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM455645.pdf).
   Google Scholar
• Pasricha PJ, Yates K, Sarosiek I, et al. Aprepitant for symptoms of gastroparesis and related disorders: the APRON randomized clinical trial. Am J Gastroenterol. 2016;111(Suppl 1):S480.
   PubMedGoogle Scholar
• Smith JAM, Beattie DT, Marquess D, et al. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity Naunyn Schmiedeberg’s. Arch Pharmacol. 2008;378:125–137.
   Web of Science ®Google Scholar
• Bowersox SS, Lightning LK, Rao S, et al. Metabolism and Pharmacokinetics of naronapride (ATI-7505), a serotonin 5-HT4 receptor agonist for gastrointestinal motility disorders. Drug Metab Dispos. 2011;39:1170–1180.
   PubMed Web of Science ®Google Scholar
• Beattie DT, Armstrong SR, Vickery RG, et al. The pharmacology of TD-8954, a potent and selective 5-HT4 receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol. 2011;2:25.
   PubMed Web of Science ®Google Scholar